The Cost of Obesity for Nonbariatric Inpatient Operative Procedures in the United States National Cost Estimates Obese versus Nonobese Patients

被引:35
|
作者
Mason, Rodney J. [1 ]
Moroney, Jolene R. [2 ]
Berne, Thomas V. [1 ]
机构
[1] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
关键词
national cost estimates of obesity; surgical costs of nonobese versus obese patients; surgical cost of obesity; TOTAL KNEE ARTHROPLASTY; HEALTH-CARE COSTS; BODY-MASS INDEX; BARIATRIC SURGERY; MORBID-OBESITY; COLORECTAL SURGERY; ECONOMIC BURDEN; US ADULTS; IMPACT; COMPLICATIONS;
D O I
10.1097/SLA.0b013e3182a500ce
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: To evaluate the economic impact of obesity on hospital costs associated with the commonest nonbariatric, nonobstetrical surgical procedures. Background: Health care costs and obesity are both rising. Nonsurgical costs associated with obesity are well documented but surgical costs are not. Methods: National cost estimates were calculated from the Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) database, 2005-2009, for the highest volume nonbariatric nonobstetric procedures. Obesity was identified from the HCUP-NIS severity data file comorbidity index. Costs for obese patients were compared with those for nonobese patients. To control for medical complexity, each obese patient was matched one-to-one with a nonobese patient using age, sex, race, and 28 comorbid defined elements. Results: Of 2,309,699 procedures, 439,8129 (19%) were successfully matched into 2 medically equal groups (obese vs nonobese). Adjusted total hospital costs incurred by obese patients were 3.7% higher with a significantly (P < 0.0001) higher per capita cost of $648 (95% confidence interval [CI]: $556-$736) compared with nonobese patients. Of the 2 major components of hospital costs, length of stay was significantly increased in obese patients (mean difference = 0.0253 days, 95% CI: 0.0225-0.0282) and resource utilization determined by costs per day were greater in obese patients due to an increased number of diagnostic and therapeutic procedures needed postoperatively (odds ratio [OR] = 0.94, 95% CI: 0.93-0.96). Postoperative complications were equivalent in both groups (OR = 0.97, 95% CI: 0.93-1.02). Conclusions: Annual national hospital expenditures for the largest volume surgical procedures is an estimated $160 million higher in obese than in a comparative group of nonobese patients.
引用
下载
收藏
页码:541 / 553
页数:13
相关论文
共 50 条
  • [31] Increase in economic burden of hip and knee replacements in the United States: Estimated from the health care cost and utilization project - National inpatient survey
    Kim, S. H.
    VALUE IN HEALTH, 2007, 10 (03) : A120 - A120
  • [32] Enoxaparin versus heparin in the treatment of patients with acute deep vein thrombosis: A cost analysis of patients treated in the United States.
    Krupski, WC
    Nehler, MR
    Whitehill, TA
    Hiatt, W
    BLOOD, 1999, 94 (10) : 183A - 183A
  • [33] OUTCOME AND COST ANALYSIS OF LEFT ATRIAL APPENDAGE OCCLUSION (LAAO) DEVICE PROCEDURE IN MORBIDLY OBESE PATIENTS: A NATIONAL INPATIENT SAMPLE DATABASE STUDY
    Ayub, Muhammad Talha
    Fratti, Juan Del Cid
    Madan, Nidhi
    Huang, Henry
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 539 - 539
  • [34] The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates
    Grosse, Scott D.
    Palomaki, Glenn E.
    Mvundura, Mercy
    Hampel, Heather
    GENETICS IN MEDICINE, 2015, 17 (06) : 510 - 511
  • [35] Pay-for-Obesity? Performance Metrics Ignore Differences in Complication Rates and Cost for Obese Patients Undergoing Two Common General Surgical Procedures
    Hirose, Kenzo
    Shore, Andrew D.
    Wick, Elizabeth C.
    Makary, Martin A.
    GASTROENTEROLOGY, 2010, 138 (05) : S849 - S849
  • [36] Cost-effectiveness of treating patients with advanced progressive pancreatic neuroendocrine tumors with everolimus versus sunitinib in the United States
    Chulikavit, Maruit
    Casciano, Roman
    Perrin, Allison
    Liu, Zhimei
    Wang, Xufang
    Babigumira, Joseph
    Grzegorzewski, Kris
    Garrison, Louis P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] COST-EFFECTIVENESS OF EFAVIRENZ VERSUS RILPIVIRINE IN HIV PATIENTS INITIATING FIRST-LINE TREATMENT IN THE UNITED STATES
    Bonafede, M.
    Juday, T.
    Lenhart, G.
    Pan, K.
    Hebden, T.
    Correll, T.
    VALUE IN HEALTH, 2012, 15 (04) : A241 - A241
  • [38] COST-EFFECTIVENESS ANALYSIS OF MIRABEGRON VERSUS TOLTERODINE EXTENDED RELEASE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN THE UNITED STATES
    Xie, J.
    Zhou, Z. Y.
    Bui, C. N.
    Yan, Y.
    De, G.
    Runken, M. C.
    Wu, E. Q.
    VALUE IN HEALTH, 2012, 15 (07) : A457 - A457
  • [39] Cost of End-of-Life Inpatient Encounters in Patients with Chronic Kidney Disease in the United States: A Report from the DISCOVER CKD Retrospective Cohort
    Pollock, Carol
    James, Glen
    Sanchez, Juan Jose Garcia
    Arnold, Matthew
    Carrero, Juan-Jesus
    Lam, Carolyn S. P.
    Chen, Hungta
    Nolan, Stephen
    Pecoits-Filho, Roberto
    ADVANCES IN THERAPY, 2022, 39 (03) : 1432 - 1445
  • [40] Cost of End-of-Life Inpatient Encounters in Patients with Chronic Kidney Disease in the United States: A Report from the DISCOVER CKD Retrospective Cohort
    Carol Pollock
    Glen James
    Juan Jose Garcia Sanchez
    Matthew Arnold
    Juan-Jesus Carrero
    Carolyn S. P. Lam
    Hungta Chen
    Stephen Nolan
    Roberto Pecoits-Filho
    Advances in Therapy, 2022, 39 : 1432 - 1445